APCCC 2022 | Updates on ADT as monotherapy for management of mHSPC

Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, comments on novel advances in the management of metastatic hormone-sensitive prostate cancer (mHSPC). Evidence suggests that androgen deprivation therapy (ADT) should rarely be offered as a monotherapy and that survival is increased when ADT is combined with drugs such as abiraterone and radiation in patients with de novo metastatic prostate cancer. Moreover, Prof. Armstrong discusses the discrepancy in receiving ADT as monotherapy between ethnic groups and possible reasons for this and comments on the importance of including participant diversity in metastatic trials. This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.